Literature DB >> 10207171

Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

B Lamarche1, K D Uffelman, A Carpentier, J S Cohn, G Steiner, P H Barrett, G F Lewis.   

Abstract

Triglyceride (TG) enrichment of HDL resulting from cholesteryl ester transfer protein-mediated exchange with TG-rich lipoproteins may enhance the lipolytic transformation and subsequent metabolic clearance of HDL particles in hypertriglyceridemic states. The present study investigates the effect of TG enrichment of HDL on the clearance of HDL-associated apo A-I in humans. HDL was isolated from plasma of six normolipidemic men (mean age: 29.7 +/- 2.7 years) in the fasting state and after a five-hour intravenous infusion with a synthetic TG emulsion, Intralipid. Intralipid infusion resulted in a 2.1-fold increase in the TG content of HDL. Each tracer was then whole-labeled with 125I or 131I and injected intravenously into the subject. Apo A-I in TG-enriched HDL was cleared 26% more rapidly than apo A-I in fasting HDL. A strong correlation between the Intralipid-induced increase in the TG content of HDL and the increase in HDL apo A-I fractional catabolic rate reinforced the importance of TG enrichment of HDL in enhancing its metabolic clearance. HDL was separated further into lipoproteins containing apo A-II (LpAI:AII) and those without apo A-II (LpAI). Results revealed that the enhanced clearance of apo A-I from TG-enriched HDL could be largely attributed to differences in the clearance of LpAI but not LpAI:AII. This is, to our knowledge, the first direct demonstration in humans that TG enrichment of HDL enhances the clearance of HDL apo A-I from the circulation. This phenomenon could provide an important mechanism explaining how HDL apo A-I and HDL cholesterol are lowered in hypertriglyceridemic states.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207171      PMCID: PMC408274          DOI: 10.1172/JCI5286

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Overestimation of the lipoprotein fractional catabolic rate (FCR) measured in short duration experiments.

Authors:  G Champarnaud; K Ouguerram; T Magot; C Lutton
Journal:  J Pharmacobiodyn       Date:  1992-09

Review 2.  Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism.

Authors:  D Reichl; N E Miller
Journal:  Arteriosclerosis       Date:  1989 Nov-Dec

3.  Clearance of postprandial and lipolytically modified human HDL in rabbits and rats.

Authors:  G F Lewis; B Lamarche; K D Uffelman; A C Heatherington; M A Honig; L W Szeto; P H Barrett
Journal:  J Lipid Res       Date:  1997-09       Impact factor: 5.922

4.  Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys.

Authors:  I J Goldberg; W S Blaner; T M Vanni; M Moukides; R Ramakrishnan
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

5.  Postprandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat-loading test.

Authors:  G F Lewis; N M O'Meara; P A Soltys; J D Blackman; P H Iverius; A F Druetzler; G S Getz; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

6.  Analysis of high density lipoproteins by a modified gradient gel electrophoresis method.

Authors:  Z Li; J R McNamara; J M Ordovas; E J Schaefer
Journal:  J Lipid Res       Date:  1994-09       Impact factor: 5.922

7.  Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia.

Authors:  E A Brinton; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

8.  Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model.

Authors:  B Lamarche; K D Uffelman; G Steiner; P H Barrett; G F Lewis
Journal:  J Lipid Res       Date:  1998-06       Impact factor: 5.922

Review 9.  Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies.

Authors:  A R Tall
Journal:  J Intern Med       Date:  1995-01       Impact factor: 8.989

10.  Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels.

Authors:  G W Melchior; C K Castle; R W Murray; W L Blake; D M Dinh; K R Marotti
Journal:  J Biol Chem       Date:  1994-03-18       Impact factor: 5.157

View more
  55 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein.

Authors:  Ke Wu; David Cappel; Melissa Martinez; John M Stafford
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 3.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 4.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

Review 5.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

6.  Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice.

Authors:  Brian T Palmisano; Thao D Le; Lin Zhu; Yoon Kwang Lee; John M Stafford
Journal:  J Lipid Res       Date:  2016-06-27       Impact factor: 5.922

7.  CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.

Authors:  Silvia Bijland; Sjoerd A A van den Berg; Peter J Voshol; Anita M van den Hoek; Hans M G Princen; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

8.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

9.  Correlation between the extent of coronary atherosclerosis and lipid profile.

Authors:  Janusz Tarchalski; Przemysław Guzik; Henryk Wysocki
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

10.  Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

Authors:  John S Millar; Danielle Duffy; Ramprasad Gadi; LeAnne T Bloedon; Richard L Dunbar; Megan L Wolfe; Rajesh Movva; Ashish Shah; Ilia V Fuki; Mary McCoy; Cynthia J Harris; Ming-Dauh Wang; Daniel C Howey; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-06       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.